Document:

<PAGE>
                                                                   Exhibit 10.13

                          TECHNOLOGY LICENSE AGREEMENT

      Agreement made as of the 1st day of February, 1999 (the "Effective Date"),
between VERTEX PHARMACEUTICALS INCORPORATED, a Massachusetts corporation
(together with its Affiliates, "Vertex"), and ALTUS BIOLOGICS INC., a
Massachusetts corporation (together with its Affiliates, "Altus").

      WHEREAS, Altus and Vertex are parties to a Technology License Agreement
dated as of December 31, 1992 (the "Old License Agreement") with respect to the
research, development, manufacturing and sale of cross-linked protein crystals
and other stabilized proteins;

      WHEREAS, each of Vertex and Altus is the respective owner of certain
patent rights, technology and intellectual property relating to protein
stabilization and has the right to transfer or grant licenses or sublicenses
under said patent rights, technology and intellectual property;

      WHEREAS, Altus and Vertex desire to terminate the Old License Agreement as
of the Effective Date and enter into a new agreement with respect to the subject
matter thereof;

      NOW THEREFORE, in consideration of the mutual covenants herein contained,
and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties hereto agree as follows:

1. DEFINITIONS

      1.1. "AFFILIATE" shall mean any corporation or legal entity which
controls, or is controlled by, or is -under common control with the designated
party. "Control" means the ownership, directly or through one or more
Affiliates, of more than fifty percent (50%) of the shares of stock entitled to
vote for the election of directors, in the case of a corporation, or more than
fifty percent (50%) of the equity interest, in the case of any other type of
legal entity.

      1.2. "ALTUS FIELD" shall mean all fields of use.

      1.3. "ALTUS MANUFACTURING KNOW-HOW" shall mean that portion of Vertex
Technology, Existing Altus Technology, Subsequent Altus Patents or Subsequent
Altus Technology which is necessary or useful in the manufacture or production
of cross-linked protein crystals.

      1.4. "COLLABORATORS" shall mean entities in collaboration with Vertex with
respect to the research, development or manufacture of Vertex Products and which
are engaged in the business of researching, developing, or manufacturing
pharmaceutical products for human or animal therapeutics, but specifically
excluding: (i) entities engaged in contract manufacturing of such Vertex
Products; (ii) entities engaged in contract process development of such Vertex
Products; and (iii) entities which are academic institutions or not-for-profit
research institutions.

      1.5. "CONFIDENTIAL INFORMATION" shall mean (i) the Vertex Technology, the
Existing Altus Technology, the Subsequent Altus Patents, or the Subsequent Altus
Technology; and (ii) any other product, technology, or information of or about
Vertex, its Collaborators, or Altus that is provided by a party to the other
party hereunder; provided, however, that "Confidential

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

<PAGE>

Information" shall not include any information described in subsections (i)
through (iv) of Section 5.3 hereof.

      1.6. "EXISTING ALTUS PATENTS" shall mean the patent applications and
patents listed on Schedule 1.6 hereto, together with any divisionals,
continuations, continuations-in-part, foreign counterparts, reissues, renewals,
reexaminations, substitutions or extensions of or to any such patent
applications or patents, and any patents issuing from any of the foregoing.
Schedule 1.6 shall be updated from time to time, but in no event less often than
once [****************], to include all patents and patent applications
comprising the Existing Altus Patents.

      1.7. "EXISTING ALTUS TECHNOLOGY" shall mean (i) the Existing Altus
Patents, (ii) any and all proprietary processes, trade secrets, technical
information, know-how, technology and other intellectual property of Altus,
whether or not patented or patentable, existing as of the Effective Date and
which are necessary or useful in the research, development, manufacture, use and
sale of products for human and animal therapeutic applications, and which are
owned, or have been acquired, developed, or licensed by Altus as of the
Effective Date, and as to which Altus has the right to grant licenses or
sublicenses in the Vertex Field.

      1.8. "LICENSED PRODUCT(S)" shall mean any product (i) the development,
manufacture, use, sale, or import of which would, but for the licenses granted
to Altus hereunder, infringe the Vertex Patents, or which is covered by a claim
of a pending patent application included in the Vertex Patents, or (ii) which is
developed, manufactured, produced or used through the use of any Vertex
Technology or which incorporates the Vertex Technology.

      1.9. "SUBSEQUENT ALTUS PATENTS" shall mean patent applications and patents
claiming Subsequent Altus Technology, and any divisions, continuations,
continuations-in-part, foreign counterparts, reissues, renewals, reexaminations,
substitutions or extensions of or to any such patent applications or patents,
and any patents issuing from any of the foregoing. Subsequent Altus Patents
shall be set forth on Schedule 1.9, and Schedule 1.9 shall be updated from time
to time, but in no event less often that once [****************], to include all
patents and patent applications comprising the Subsequent Altus Patents.

      1.10. "SUBSEQUENT ALTUS TECHNOLOGY" shall mean any and all proprietary
processes, trade secrets, technical information, know-how, technology and
intellectual property of Altus with respect to cross-linked protein crystals,
whether or not patented or patentable, which are necessary or useful in the
research, development, manufacture, use and sale of products for human and
animal therapeutic applications and which are acquired, developed, or licensed
by Altus during the five (5) year period beginning on the Effective Date, and as
to which Altus has the right to grant licenses or sublicenses in the Vertex
Field.

      1.11. "THIRD PARTY" means any entity other than Vertex and its Affiliates
or Collaborators, or Altus and its Affiliates.

      1.12. "VERTEX FIELD" shall mean small molecule drugs for human and animal
therapeutic uses.

      1.13. "VERTEX PATENTS" shall mean (i) the patent applications and patents
listed on Schedule 1.13 hereto; and (ii) any patent applications and patents
claiming Vertex Technology

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                      -2-
<PAGE>

identified in Section 1.15(iii) below, together with any divisionals,
continuations, continuations-in-part, foreign counterparts, reissues, renewals,
reexaminations, substitutions or extensions of or to any such patent
applications or patents, and any patents issuing from any of the foregoing.
Schedule 1.13 shall be updated from time to time, but in no event less often
than [*********************], to include all patent applications and patents
comprising the Vertex Patents, including, without limitation, all patent
applications filed after the Effective Date and claiming Vertex Technology
identified in Section 1.15 (iii) below.

      1.14. "VERTEX PRODUCT" shall mean any small molecule drug researched,
discovered, developed or produced for human or animal therapeutic uses using the
Subsequent Altus Patents, the Subsequent Altus Technology, the Vertex Technology
or the Existing Altus Technology.

      1.15. "VERTEX TECHNOLOGY" shall mean (i) the Vertex Patents, (ii) any and
all proprietary processes, trade secrets, technical information, know-how,
technology and other intellectual property of Vertex claimed in or relating to
the Vertex Patents, or which is necessary or useful to practice the technology
described in the Vertex Patents existing on the Effective Date and, on the
Effective Date of this Agreement, owned or licensed to Vertex with the right to
grant licenses or sublicenses thereunder, and (iii) any and all proprietary
processes, trade secrets, technical information, know-how, and other
intellectual property, whether or not patented or patentable, first developed,
conceived or reduced to practice by Vertex or its Collaborators within five (5)
years after the Effective Date, which constitutes an improvement to the
technology described in clause 1.15(i) or 1.15(ii) above, and as to which Vertex
has the right to grant licenses or sublicenses.

2. LICENSES GRANTED: TERMINATION OF OLD LICENSE AGREEMENT

      2.1. License to Altus Under Vertex Technology.

      Vertex hereby grants to Altus an exclusive, worldwide, royalty-free,
fully-paid right and license in the Altus Field under the Vertex Technology to
develop, make, use, sell, and import Licensed Products; provided, however, that
Vertex shall retain non-exclusive rights for itself and its Collaborators in the
Vertex Field under the Vertex Technology to develop, make, use, sell, and import
Vertex Products; and provided, further, that Vertex shall give Altus prompt
notice of any such use or access to the Vertex Technology by its Collaborators.
Vertex will make available to Altus, at such time or times and in such manner as
Altus shall reasonably request, such written or oral information and documents
as constitute the Vertex Technology. Altus shall have the right to grant
sublicenses to Third Parties under the Vertex Technology, provided, that, it
shall give Vertex prompt notice of each such sublicense granted. Neither Vertex
nor its Collaborators shall have the right to grant rights or licenses under the
Vertex Technology to any Third Party, except as permitted by Section 2.3 hereof.

      2.2. License to Vertex Under Existing Altus Technology, Subsequent Altus
Patents and Subsequent Altus Technology. Altus hereby grants to Vertex a
nonexclusive, worldwide, royalty-free, fully-paid right and license in the
Vertex Field under the Existing Altus Technology, the Subsequent Altus Patents,
and the Subsequent Altus Technology, to develop, make, use, sell, and import
Vertex Products. Altus will make available to Vertex, at such time or times and
in such manner as Vertex shall reasonably request, such written or oral
information

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                      -3-
<PAGE>

and documents as constitute the Existing Altus Technology and the Subsequent
Altus Technology. Vertex shall have the right to grant sublicenses hereunder to
Collaborators in the Vertex Field; provided, that, it shall give Altus prompt
notice of each such sublicense granted; and provided, further, that Altus
Manufacturing Know-How shall not be disclosed or sublicensed to a Collaborator
except as provided in Section 2.3.

      2.3. Altus Manufacturing Know-How.

      (a) Vertex may disclose, license and/or sublicense Altus Manufacturing
Know-How to its Collaborators, solely for the purpose of permitting such
Collaborators to develop, make, use, sell, or import any Vertex Products;
provided, that, each such Collaborator shall first enter into confidentiality
and non-use agreements with Vertex upon terms at least as restrictive as those
set forth in Section 5 hereof. The Altus Manufacturing Know-How shall only be
disclosed to those employees of such Collaborators who have a specific need to
access and/or use the Altus Manufacturing Know-How for purposes permitted by
this Agreement. Vertex agrees to use commercially reasonable good faith efforts
to limit, where possible, its disclosure of Altus Manufacturing Know-How to
Collaborators.

      (b) In the event that Vertex requires the manufacture or production of
cross-linked protein crystals, Vertex may elect, in its sole judgment: (x) to
conduct such manufacture or production itself; (y) to conduct such manufacture
or production through one or more Collaborators; or (z) to cause Altus to
manufacture and produce Vertex's requirements of cross-linked protein crystals
on commercially reasonable terms. If Altus is unable or unwilling to manufacture
and produce Vertex's requirements of cross-linked protein crystals on terms
reasonably acceptable to Vertex, Vertex may: (yy) require Altus to manufacture,
produce and supply the same at a price equal to the [******]to produce the
cross-linked protein crystals plus [***************], or (zz) cause a Third
Party to manufacture, produce, and supply such requirements. Selection of such
Third Party shall require Altus's consent, such consent not to be unreasonably
withheld or delayed. (As used in this subsection, [*********] shall mean
[***********] of producing the cross-linked protein crystals, plus a reasonable
allocation of [************].)

      (c) If Vertex selects a Third Party to manufacture, produce and supply its
requirements for cross-linked protein crystals pursuant to clause (b)(zz) above,
then, upon receipt of Altus' consent as provided under Section 2.3(b) above,
Vertex may disclose, license and/or grant sublicenses with respect to Altus
Manufacturing Know-How to such Third Party solely for purposes of manufacturing,
producing and supplying Vertex's requirements for cross-linked protein crystals;
provided, that, such Third Party shall first enter into confidentiality and
non-use agreements with Vertex upon terms at least as restrictive as those set
forth in Section 5 hereof. The Altus Manufacturing Know-How shall only be
disclosed to those employees of such Third Party who have a specific need to
access and/or use the Altus Manufacturing Know-How for the purposes permitted
under this Agreement. Vertex agrees to use commercially reasonable good faith
efforts to limit, where possible, its disclosure of Altus Manufacturing Know-How
to Third Parties.

      2.4. Old License Agreement Terminated. The Old License Agreement is
terminated as of the Effective Date, except for the provisions of Section 6
thereof ("Confidentiality"), which

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                      -4-
<PAGE>

shall survive such termination; provided, however, that to the extent Section 5
of this Agreement may conflict with Section 6 of the Old License Agreement,
Section 5 of this Agreement shall govern.

      2.5. Trademark. The parties acknowledge that the trademarks "CLECO(R)" and
"CLECs(R)" and all rights thereunder have previously been assigned to Altus by
Vertex pursuant to an instrument dated September 27, 1996 and recorded with the
United States Patent and Trademark Office on October 11, 1996.

3. PATENT PROSECUTION

      3.1. Altus shall be responsible for the preparation, filing, prosecution
and maintenance of the Vertex Patents, the Existing Altus Patents and the
Subsequent Altus Patents. Altus agrees to provide Vertex with [*******] updates
regarding the status (as such status relates to the Vertex Field) of all patent
applications and/or patents comprising the Vertex Patents, the Existing Altus
Patents and the Subsequent Altus Patents, and to respond in good faith to any
reasonable inquiries of Vertex regarding the status and/or scope of such patents
and/or patent applications. Vertex agrees to cooperate fully with Altus to
provide such consultation and assistance as may be necessary, or as is requested
by Altus, in the preparation, prosecution, filing and maintenance of such
patents or patent applications. Any information provided by Altus to Vertex
pursuant to this Section 3.1. shall be treated as the Confidential Information
of Altus hereunder.

      3.2. In the event that Altus decides to abandon or to cease prosecution or
fails to maintain a patent or patent applications included in the Vertex
Patents, the Existing Altus Patents or the Subsequent Altus Patents in any
jurisdiction, Vertex shall have the right, at its expense, to prepare, file,
prosecute and maintain the applicable patent(s) or patent application(s) in such
jurisdiction.

4. INFRINGEMENT

      4.1. Each party shall promptly notify the other of infringement or alleged
infringement of any patent or other proprietary right included in the Vertex
Technology, the Existing Altus Technology, the Subsequent Altus Patents or the
Subsequent Altus Technology, or of any unauthorized or alleged unauthorized use
thereof, which comes to its attention. In such event, the parties shall confer
promptly with respect to the assertion of proprietary rights or to the
initiation and prosecution of litigation against the alleged infringer or
unauthorized user. If the parties agree to proceed jointly, they shall
[*************] with one another, in such proportions as they may mutually agree
upon from time to time, (i) [**********************], and (ii) [***************
***********].

      4.2. If any claim, litigation or proceeding is threatened or brought by
any person against a party alleging that any use, application or disclosure of
the Vertex Technology, the Existing Altus Technology, the Subsequent Altus
Patents, or the Subsequent Altus Technology as contemplated by this Agreement
infringes any patent or other proprietary right held by such person, the parties
shall promptly confer with respect to such claim, litigation or proceeding. If
the parties agree to proceed jointly in the defense of such claim, litigation or
proceeding, the

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                      -5-
<PAGE>

parties shall [*************] with one another, in such proportions as they may
mutually agree upon from time to time, [***************************************
*******].

      4.3. Neither party shall settle or compromise any claim, litigation or
proceeding described in Section 4.1 or 4.2 hereof without the consent of the
other party, such consent not to be unreasonably withheld or delayed.

5. CONFIDENTIALITY

      5.1. Vertex shall keep confidential, and shall require its Collaborators
to keep confidential, all Vertex Technology, Existing Altus Technology,
Subsequent Altus Patents and Subsequent Altus Technology, and Altus shall keep
confidential all Vertex Technology, and each party shall keep confidential any
other Confidential Information received from the other party. Neither party
shall use the other party's Technology or Confidential Information for any
purpose other than as permitted under this Agreement, without the prior written
consent of the other party. Each party shall take all reasonable steps necessary
to insure such confidential treatment and nonuse.

      5.2. The foregoing obligations of confidential treatment and nonuse shall
not prevent the disclosure of Vertex Technology, Existing Altus Technology or
Subsequent Altus Technology by Vertex to its Collaborators who have entered into
confidentiality and nonuse agreements with Vertex on terms at least as
restrictive as those set forth in this Section 5; provided, that, Vertex's
disclosure of Altus Manufacturing Know-How shall also be subject to the
restrictions set forth elsewhere in this Agreement, including without limitation
the restrictions set forth in Section 2.2. The foregoing obligations of
confidential treatment and nonuse shall not prevent the disclosure of Vertex
Technology by Altus to its collaborators or sublicensees who have entered into
confidentiality and nonuse agreements with Altus on terms at least as
restrictive as those set forth in this Section 5.

      5.3. The foregoing obligations of confidential treatment and nonuse shall
not apply to information which the receiving party shall sustain the burden of
proving:

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                      -6-
<PAGE>

            (a) was in the possession of the receiving party, other than under
an obligation of confidentiality, prior to receipt thereof from the disclosing
party, as shown by the receiving party's written records;

            (b) was already available to the public at the time of its
disclosure to the receiving party or became available to the public after its
disclosure to the receiving party other than through a breach of this Agreement
by the receiving party;

            (c) was received by the receiving party from a third party who had
no obligation not to disclose such information to others; or

            (d) is required to be disclosed by applicable law or regulation;
provided that, prior to any such disclosure, the party intending to make such
disclosure shall give the other party reasonable advance notice and shall use
its best efforts to obtain confidential treatment of the information to be
disclosed.

      5.4. The obligations of confidentiality hereunder shall survive any
expiration or termination of this Agreement.

6. PUBLICATIONS

      Altus and its employees, on the one hand, and Vertex and its employees, on
the other hand, will be free to publicly disclose (through journals, lectures,
or otherwise) research results generated through use of the Vertex Technology,
the Existing Altus Technology or the Subsequent Altus Technology, provided in
each case that the disclosing party shall have provided a copy of the proposed
disclosure to the other party for review at least [**************] prior to the
submission of any written publication or any oral public disclosure. During such
[*************] period the non-disclosing party shall review the proposed
disclosure and, prior to the expiration of such [*************] period shall
notify the disclosing party as to whether a patent application should be filed,
whether the proposed disclosure contains information the non-disclosing party
wishes to maintain as a trade secret, or whether the proposed disclosure
contains the Confidential Information of the non-disclosing party. In the event
that the non-disclosing party believes a patent application should be filed, the
disclosing party agrees to delay publication and disclosure of the proposed
disclosure until such time as a patent application is filed. If the
non-disclosing party reports that the proposed disclosure contains Confidential
Information, or if the non-disclosing party wishes to maintain certain
information as a trade secret, the disclosing party agrees to remove such
information from the proposed disclosure.

7. REPRESENTATIONS AND WARRANTIES

      7.1. Right to Enter Agreement. Each party represents and warrants to the
other that it has the unencumbered right to enter into this Agreement and to
grant all rights granted herein and that it has not made or executed any
agreement in conflict herewith.

      7.2. Rights to Technology. Vertex represents that it is the owner of the
Vertex Technology and that it has the right to license the Vertex Technology as
set forth herein. Altus

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                      -7-
<PAGE>

represents that it has the right to license the Existing Altus Technology and
the Subsequent Altus Technology as set forth herein.

      7.3. Exclusion of Warranties. Nothing herein shall be construed as a
representation or warranty by either party:

            (a) that the utilization of its Technology does not or will not
constitute infringement of patent rights of others;

            (b) as to the results to be attained by the utilization of its
Technology;

            (c) that there is any warranty relating to its Technology, including
without limitation any warranty of merchantability or fitness for a particular
purpose, other than as expressly described herein.

      7.4. No Actual Knowledge. Notwithstanding the foregoing, each party
represents and warrants to the other that it does not have any actual knowledge
that the utilization of its Technology would constitute infringement of
presently existing valid patents of others.

8. INDEMNIFICATION AND INSURANCE

      8.1. Altus Indemnity Obligations. Altus (the "Indemnitor") agrees to
defend, indemnify and hold Vertex, its Affiliates and their respective
directors, officers, employees, consultants, agents, successors and assigns (the
"Indemnitees") harmless from [*******], judgments, liabilities, damages, losses
or expenses [***************************************************************]
incurred by or imposed on the Indemnitees or any one of them in connection with:
(i) actual or asserted violations of any applicable law or regulation by Altus
or its Affiliates by virtue of which Licensed Products manufactured, distributed
or sold by Altus or its Affiliates shall be alleged or determined to be
adulterated, misbranded, mislabeled or otherwise not in compliance with such
applicable law or regulation; (ii) claims, suits, actions, demands, or judgments
arising out of any theory of product liability (including but not limited to
actions in the form of tort, warranty or strict liability) concerning any
Licensed Product sold, manufactured, used or distributed by Altus or its
Affiliates, (iii) a recall ordered by a governmental agency, or required by a
confirmed failure, of Licensed Products manufactured, distributed, or sold by
Altus or its Affiliates; or (iv) a breach by Altus of any of its representations
and warranties made pursuant to Section 7.

      8.2. Vertex Indemnity Obligations. Vertex (the "Indemnitor") agrees to
defend, indemnify and hold Altus and its respective directors, officers,
employees, consultants, agents, successors and assignees (the "Indemnitees")
harmless from [*******], judgments, liabilities, damages, losses or expenses
[**************************************** **********************] incurred by or
imposed on the Indemnitees or any one of them in connection with: (i) actual or
asserted violations of any applicable law or regulation by Vertex or its
Affiliates or Collaborators by virtue of which Vertex Products manufactured,
distributed or sold by Vertex, its Affiliates or Collaborators shall be alleged
or determined to be adulterated, misbranded, mislabeled or otherwise not in
compliance with such applicable law or regulation; (ii) claims, suits, actions,
demands, or judgments arising out of any theory of product liability (including
but not limited to actions in the form of tort, warranty or strict liability)
concerning

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                      -8-
<PAGE>

any Vertex Product sold, manufactured, used or distributed by Vertex, its
Affiliates or Collaborators; (iii) a recall ordered by a governmental agency, or
required by a confirmed failure, of Vertex Products manufactured, distributed,
or sold by Vertex, its Affiliates or Collaborators; or (iv) a breach by Vertex
of any of its representations and warranties made pursuant to Section 7.

      8.3. Limitation on Indemnity Obligations. Neither party, nor its
Affiliates or Collaborators (in the case of Vertex), nor its and their
respective employees and agents, shall be entitled to the indemnities set forth
in this Section 8 where the claim, loss, damage or expense for which
indemnification is sought was caused by a negligent act or intentional act of
misconduct or omission by such party, its directors, officers, employees or
authorized agents.

      8.4. Procedure. In the event that an Indemnitee intends to claim
indemnification under this Section 8, such Indemnitee shall promptly notify the
Indemnitor of any loss, claim, damage, liability or action in respect of which
the Indemnitee intends to claim such Indemnification, and the Indemnitor shall
assume the defense thereof with counsel mutually satisfactory to the parties;
provided, however, that an Indemnitee shall have the right to retain its own
counsel, [*****************************************************], if
representation of such Indemnitee by the counsel retained by the Indemnitor
would be inappropriate due to actual or potential differing interests between
such Indemnitee and any other party represented by such counsel in such
proceedings. The indemnity agreement in this Section 8 shall not apply to
amounts paid in settlement of any loss, claim, damage, liability or action if
such settlement is effected without, the consent of the Indemnitor, which
consent shall not be withheld unreasonably. The failure to deliver notice to the
Indemnitor within a reasonable time after the commencement of any such action,
if prejudicial to its ability to defend such action, shall relieve the
Indemnitor of any liability to the Indemnitee under this Section 8, but the
omission so to deliver notice to the Indemnitor will not relieve it of any
liability that it may have to any Indemnitee otherwise than under this Section
8. The Indemnitee under this Section 8, its employees and agents, shall
cooperate fully with the Indemnitor and its legal representatives in the
investigation of any action, claim or liability covered by this indemnification.

9. TERM AND TERMINATION

      9.1. Term. This Agreement shall continue in full force and effect until
terminated as provided herein; provided that, with respect to the Vertex
Patents, the Existing Altus Patents or the Subsequent Altus Patents, the
licenses granted thereunder shall expire on a patent-by-patent and
country-by-country basis upon the expiration or invalidation of each patent
included in the Vertex Patents, the Existing Altus Patents or the Subsequent
Altus Patents, as the case may be.

      9.2. Termination. This Agreement may be terminated by either party in case
of a material violation or breach of any provision of this Agreement by the
other, which breach or default is not corrected within 90 days after receipt of
written notice specifying the violation or breach of this Agreement, or, if such
default cannot be cured or remedied within such ninety (90) day period, if the
party in default does not commence and diligently continue actions to cure or
remedy such default. This Agreement may also be terminated at the option of
either party upon written notice to the other party if (i) a party is unable to
pay its material financial obligations as they become due, (ii) if a voluntary
or involuntary petition in bankruptcy is filed by or against

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                      -9-
<PAGE>

such party and is thereafter either consented to, acquiesced in or remains
undismissed for 90 days, or (iii) if such party makes a general assignment for
the benefit of creditors or if a receiver is appointed for any such party.
Termination by reason of clause (i) above shall be rescinded by the terminating
party, and this Agreement shall continue in full force and effect, if within one
hundred eighty (180) days the defaulting party's financial situation has.
improved such that it is paying, and reasonably appears likely to be able to
continue to pay, its material financial obligations as they become due.

      9.3. Rights After Termination. In the event this Agreement is terminated
pursuant to Section 9.2 above, all licenses granted to the non-terminating party
hereunder shall terminate but the terminating party shall retain all rights and
licenses granted to it hereunder.

10. GENERAL

      10.1. Benefit. This Agreement shall be binding upon the parties hereto and
shall inure to the benefit of the respective successors and permitted assigns of
each party. Nothing in this Agreement shall be construed to create any rights or
obligations except between the parties hereto, and no person or entity shall be
regarded as a third-party beneficiary of this Agreement.

      10.2. Severability. In the event that any court of competent jurisdiction
shall determine that any provisions, or any portion thereof, contained in this
Agreement shall be unreasonable or unenforceable in any respect, then such
provision shall be deemed limited to the extent that such court deems it
reasonable and enforceable, and as so limited shall remain in full force and
effect. In the event that such court shall. deem any such provision, or portion
thereof, wholly unenforceable, the remaining provisions of this Agreement shall
nevertheless remain in full force and effect, provided, that if without such
invalid provisions, the fundamental mutual objectives of the parties cannot be
achieved, then either party may terminate this Agreement without penalty by
written notice to the other.

      10.3. Governing Law. This Agreement shall be governed by and construed and
interpreted in accordance with the laws of the Commonwealth of Massachusetts, as
applied to contracts entered into and performed entirely in Massachusetts by
Massachusetts residents.

      10.4. Force Majeure. Neither party shall be responsible to the other for
any failure or delay in performing any of its obligations under this Agreement
if such delay or nonperformance is caused by strike, labor stoppage, lockout or
other labor trouble, fire, flood, accident, act of God or of the Government, or
by other cause unavoidable or beyond the control of such party, provided that
prompt notice is given of the cause for the delay or nonperformance and diligent
continuing efforts are made to resume performance.

      10.5. Nonassignability. This Agreement and the licenses granted herein
shall not be assignable by either party hereto, except to a wholly-owned
subsidiary or to a successor to all or substantially all of such party's
business without the prior written consent of the other party, such consent not
to be unreasonably withheld or delayed.

      10.6. Entire Agreement: Modification. This Agreement constitutes the
entire understanding between the parties hereto with respect to the subject
matter hereof and, except as set forth in Section 2.3 hereof, supersedes all
prior agreements, written or oral, with respect

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                      -10-
<PAGE>

thereto. Only the licenses granted pursuant to the express terms of this
Agreement shall be of any legal force and effect. No license rights shall be
created by implication or estoppel. No modification or amendment hereof shall be
valid or binding upon the parties hereto unless made in writing and duly
executed on behalf of both parties.

      10.7. Waiver. No actual waiver of breach or default by a party of any
provision of this Agreement shall be deemed or construed to be a waiver of any
succeeding breach or default of the same or any other provision.

      10.8. Notice. Any notice or other communication required or permitted to
be given hereunder shall be sufficient if (i) delivered by hand, (ii) made by
telecopy or facsimile transmission, (iii) sent by overnight courier, or (iv) by
certified or registered mail, return receipt requested, postage prepaid,
addressed as follows:

If to Altus, to:

      Altus Biologics Inc.
      625 Putnam Street
      Cambridge, MA 02139
      Attention: President

If to Vertex, to:

      Vertex Pharmaceuticals Incorporated
      130 Waverly Street
      Cambridge, MA 02139
      Attention: Chief Business Officer

or, in each case, to such other address as may be designated by written notice
given in the manner herein provided. Time of notice or other communication shall
be deemed to be the date of receipt.

      10.9. Headings. Titles or headings of articles, sections, or paragraphs
contained in this Agreement are inserted only as a matter of convenience and for
reference, and in no way are intended to define, limit, extend, or describe the
scope of this Agreement or the intent of any provision hereof.

      10.10. Counterparts. This Agreement may be executed in a number of
counterparts, all of which together shall constitute one Agreement.

      10.11. Relationship of Parties. For purposes of this Agreement, each party
is an independent contractor and not an agent or employee of the other party.
Neither party shall have any authority to make any statements, representations,
or commitments of any kind, or to take any action which shall be binding upon
the other party, except as may be explicitly provided for in this Agreement or
authorized in writing by the other party.

      10.12. Dispute Resolution.

            (a) Any dispute, controversy or claim (a "Dispute") arising pursuant
to this Agreement shall first be addressed by good faith, amicable discussion
between the chief

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                      -11-
<PAGE>

executive officers of Vertex and Altus (the "Senior Executives"). Within
[***********] of notice by a party to the other party of the existence of a
Dispute, the Senior Executives shall meet for the purpose of discussing and
resolving the Dispute at a mutually acceptable time and location. If a
settlement of the Dispute is not achieved by the Senior Executives within
[**************] of the date of the notice of the Dispute (which period may be
extended by mutual agreement of the Senior Executives) subject to any rights to
injunctive relief, such Dispute shall be resolved by binding arbitration as
provided in Section 10.12(b) below.

            (b) Any Dispute not resolved by the parties pursuant to Section
10.12(a) above shall be submitted to binding arbitration conducted under the
Commercial Rules of the American Arbitration Association. Such arbitration shall
be conducted by a panel of three (3) arbitrators appointed in accordance with
such rules and who shall have experience in resolving disputes among parties in
the biotechnology industry. Each arbitrator shall be required to enter into a
confidentiality agreement with respect to any Confidential Information disclosed
to him or her in connection with the Dispute. The arbitration shall be conducted
in Cambridge, Massachusetts. The Federal Rules of Civil Procedure shall apply to
such arbitration. The arbitrators shall be required to reach a decision with
respect to the Dispute and report the same to the parties as soon as reasonable
considering the type and range of issues presented by the Dispute, but in any
event no later than [***************************] from the date of appointment
of the panel of three arbitrators.

            (c) The parties hereto agree to be bound by the decision of such
arbitrators, and that the payment of any and all legal fees in connection with
the arbitration of any Dispute hereunder shall be allocated by such arbitrators.
Judgment upon the award rendered may be entered in any court having jurisdiction
with respect thereto.

            (d) Nothing in the foregoing shall prevent either party from seeking
immediate injunctive or other provisional relief, without otherwise resorting to
the foregoing remedies, in order to protect its rights under this Agreement or
to compel the other party to comply with its obligations hereunder.

                      [THIS SPACE INTENTIONALLY LEFT BLANK]

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                      -12-
<PAGE>

         IN WITNESS WHEREOF; the parties hereto have duly executed this
Agreement as of the date first written above.

VERTEX PHARMACEUTICALS                       ALTUS BIOLOGICS INC.
INCORPORATED

By: /s/ Thomas G. Auchincloss                By: /s/ Peter Lanciano
    ----------------------------                 ----------------------
    Thomas G. Auchincloss, Jr.                   Peter Lanciano
    Vice President, Finance                      President

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                      -13-
<PAGE>

                                  SCHEDULE 1.6
                                       TO
                          TECHNOLOGY LICENSE AGREEMENT
                                     BETWEEN
          VERTEX PHARMACEUTICALS INCORPORATED AND ALTUS BIOLOGICS INC.

                             EXISTING ALTUS PATENTS

<TABLE>
<CAPTION>
Country                         Serial No.                       Filing Date
<S>                             <C>                              <C>
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
</TABLE>

<TABLE>
<CAPTION>
Country                         Serial No.                       Filing Date
<S>                             <C>                              <C>
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
</TABLE>

<TABLE>
<CAPTION>
Country                         Serial No.                       Filing Date
<S>                             <C>                              <C>
[***]                            [***]                             [***]
</TABLE>

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       14
<PAGE>

<TABLE>
<S>                              <C>                               <C>
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                                                              [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
</TABLE>

<TABLE>
<S>                              <C>                               <C>
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
[***]                            [***]                             [***]
</TABLE>

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       15
<PAGE>

<TABLE>
<CAPTION>
Country                            Serial No.                        Filing Date
<S>                                <C>                               <C>
[***]                                [***]                             [***]
[***]                                [***]                             [***]
</TABLE>

<TABLE>
<CAPTION>
Country                            Serial No.                        Filing Date
<S>                                <C>                               <C>
[***]                                [***]                             [***]
</TABLE>

<TABLE>
<CAPTION>
Country                            Serial No.                        Filing Date
<S>                                <C>                               <C>
[***]                                [***]                             [***]
</TABLE>

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       16
<PAGE>

                                  SCHEDULE 1.9
                                       TO
                          TECHNOLOGY LICENSE AGREEMENT
                                     BETWEEN
          VERTEX PHARMACEUTICALS INCORPORATED AND ALTUS BIOLOGICS INC.

                            SUBSEQUENT ALTUS PATENTS

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       17
<PAGE>

                                  SCHEDULE 1.13
                                       TO
                          TECHNOLOGY LICENSE AGREEMENT
                                     BETWEEN
          VERTEX PHARMACEUTICALS INCORPORATED AND ALTUS BIOLOGICS INC.

                                 VERTEX PATENTS

<TABLE>
<CAPTION>
Country                           Serial No.                     Filing Date
<S>                               <C>                            <C>
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]
[***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
</TABLE>

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       18
<PAGE>
<TABLE>
<S>                                 <C>                              <C>
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
</TABLE>

<TABLE>
<CAPTION>
Country                           Serial No.                       Filing Date
<S>                               <C>                              <C>
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
[***]                               [***]                            [***]
</TABLE>

                         12 PATENTS EXCLUSIVELY LICENSED
                        TO ALTUS AS OF FEBRUARY 18, 1999

<TABLE>
<CAPTION>
Country                  Serial No.                   Filing Date                  Patent No.
<S>                      <C>                          <C>                          <C>
[***]                      [***]                        [***]                        [***]
[***]                      [***]                        [***]                        [***]
[***]                      [***]                        [***]                        [***]
[***]                      [***]                        [***]                        [***]
[***]                      [***]                        [***]                        [***]
[***]                      [***]                        [***]                        [***]
[***]                      [***]                        [***]                        [***]
[***]                      [***]                        [***]                        [***]
[***]                      [***]                        [***]                        [***]
</TABLE>

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       19
<PAGE>

<TABLE>
<CAPTION>
Country                       Serial No.                   Filing Date                  Patent No.
<S>                           <C>                          <C>                          <C>
[***]                           [***]                        [***]                        [***]
</TABLE>

<TABLE>
<CAPTION>
Country                       Serial No.                   Filing Date                  Patent No.
<S>                           <C>                          <C>                          <C>
[***]                           [***]                        [***]                        [***]
[***]                           [***]                        [***]                        [***]
</TABLE>

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       20<PAGE>
                                                                   Exhibit 10.14

                        COOPERATIVE DEVELOPMENT AGREEMENT

      THIS AGREEMENT, entered into as of the 8th day of November, 2002, by and
between ALTUS BIOLOGICS INC., a corporation organized and existing under the
laws of the State of Delaware and having its principal place of business at 625
Putnam Avenue, Cambridge, MA 02139 (hereinafter called "ALTUS"), and AMANO
ENZYME INC., a corporation organized and existing under the laws of Japan and
having its principal place of business at 1-2-7, Nishiki, Naka-ku, Nagoya, Japan
(hereinafter called "AMANO"),

                                   WITNESSETH:

WHEREAS, ALTUS, through research and development for a long time, acquires and
possesses certain valuable technologies pertaining to certain pharmaceutical
products known as TheraCLEC(TM) Total and a method for manufacturing such
products and continues to develop scientific techniques pertaining to the
products, and owns and controls certain patent rights and trademark rights in
the products, and

WHEREAS, AMANO has, over the years, demonstrated its expertise in development,
manufacturing and worldwide marketing of many kind of enzymes for the commercial
markets especially in food industry and pharmaceutical industry, and has thereby
established a reputation of high regard in such markets, which reputation is
believed by ALTUS to be of great value to the possible success of the joint
development contemplated hereunder, and

WHEREAS, AMANO desires to undertake manufacture of enzyme materials to be used
in the products of ALTUS,

WHEREAS, ALTUS and AMANO are willing to enter into a cooperative development of
certain enzyme materials, which are fit for TheraCLEC(TM) Total, and entire
specifications of which are instructed by ALTUS, and

WHEREAS, ALTUS and AMANO propose to decide at the end of Phase II of the U.S.
clinical trial process whether they will enter into a further manufacturing
agreement.

NOW, THEREFORE, ALTUS and AMANO agree as follows:

ARTICLE 1. DEFINITIONS

1.    The term "Products" shall mean the pharmaceutical products known as
      TheraCLEC(TM) Total, in a certain preparation form or forms intended for
      therapeutic use in humans specified, developed, manufactured, labeled and
      packaged and sold by or on behalf of ALTUS.

2.    The term "Materials" shall mean enzymes used as active ingredients in the
      Products, which are made up of selected [***********] and [******]
      prepared by AMANO in accordance with Specifications developed and
      submitted by ALTUS for use in manufacturing Products.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       1
<PAGE>

3.    The term "Amano Enzymes" shall mean enzymes including but not limited to
      [**************] and [********], which are discovered, invented,
      developed, produced, sold or otherwise disposed by Amano with its sole
      technologies and which are basis of Materials to be develop hereunder.

4.    The term "Technical Information" shall mean all of the information and
      knowledge now possessed by ALTUS or AMANO and those acquired by ALTUS or
      AMANO during the life of this Agreement, which relate to manufacturing
      process of Materials -or relate to Products.

5.    The term "ALTUS's Development" shall mean any and all works of research
      and development made by ALTUS with respect to Materials and Products to be
      developed hereunder.

6.    The term "AMANO's Development" shall mean any and all works of research
      and development made by AMANO with respect to Materials to be developed
      hereunder.

7.    The term "Joint Development" shall mean any and all technical works of
      research and development jointly made by ALTUS and AMANO with respect to
      Materials to be developed hereunder.

8.    The term "Development" shall mean ALTUS's Development, AMANO's Development
      and/or Joint Development.

9.    The term "ALTUS's Technologies" shall mean any and all technologies now
      possessed by ALTUS and those acquired by ALTUS during the life of this
      Agreement.

10.   The term "AMANO's Technologies" shall mean any and all technologies now
      possessed by AMANO and those acquired by AMANO during the life of this
      Agreement.

11.   The term "Joint Technologies" shall mean any and all technologies jointly
      developed by ALTUS and AMANO as the results of working together during the
      life of this Agreement, which relate to manufacturing process of
      Materials.

12.   The term "Patents" shall mean those patents and patent applications which
      either party owns or controls or which either party may obtain or both the
      parties may jointly obtain hereunder, the application date of which is on
      or before the date of this Agreement or during the life of this Agreement,
      and all of which are useful for or relating to Materials and/or Products.

13.   The term "Specifications" shall mean the written specifications
      established for the characteristics, quality and quality control testing
      procedures for each of Materials as developed by ALTUS, and as amended or
      supplemented from time to time.

14.   The term "Good Manufacturing Practices" shall mean good manufacturing
      practices as defined in applicable laws, regulations and guidelines.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       2
<PAGE>

ARTICLE 2. PURPOSES

ALTUS and AMANO shall together and individually make Development toward the goal
of successfully manufacturing Materials to be used in Products. ALTUS and AMANO
shall exert [************] to successfully complete Development under the terms
and conditions of this Agreement.

ARTICLE 3. RESPECTIVE CHARGES OF DEVELOPMENT

1.    ALTUS shall take charge of clinical development in the nature and
      characteristic of Materials used for the preparation of Products, and
      chemical reaction and effect against malabsorption resulting from
      pancreatic insufficiency including cystic fibrosis, and carry out such
      development at ALTUS's laboratory and AMANO's facility during the life of
      this Agreement. In the course of ALTUS's Development, ALTUS shall:

      1)    develop and establish ALTUS's Technologies utilized in Materials as
            bulk drug active for Products,

      2)    develop and establish the standard of Specifications of Materials to
            be manufactured by AMANO and prototype manufacturing processes
            therefor,

      3)    transfer to AMANO Specifications to be employed by AMANO and give
            AMANO a technical guidance in the manufacture of Materials,
            particularly TheraCLEC [******] and [**************] and [********],

      4)    inspect and approve AMANO's Development,

      5)    prepare and realize an Investigational New Drug application ("IND")
            to the Food and Drug Administration ("FDA") for Materials and/or
            Products,

      6)    provide assistance to AMANO in establishing Good Manufacturing
            Practices, and

      7)    perfect the regulatory process and retain records pertaining to
            development of the Materials and Products.

2.    AMANO shall take charge of development in the manufacture of Materials and
      carry out such development at AMANO's laboratory during the life of this
      Agreement. In the course of AMANO's Development, AMANO shall:

      1)    arrange production facility located in Japan for Materials, which
            meets requirement of Good Manufacturing Practices,

      2)    establish AMANO's Technologies of [*********************] and
            [*************************] for Materials,

      3)    establish AMANO's Technologies of the [*******] and
            [****************] for materials,

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       3
<PAGE>

      4)    develop technologies manufacturing TheraCLEC [******] and
            [*************] and [********] under AMANO's Technologies in
            accordance with ALTUS's Technologies disclosed to AMANO,

      5)    develop AMANO's Technologies of manufacturing Materials in
            accordance with Specifications and guidance given by ALTUS, and

      6)    support the regulatory process and retain records pertaining to
            development of the Materials.

3.    ALTUS and AMANO shall jointly develop and establish a standard
      manufacturing management protocol for Materials on the basis of quality
      control procedures originally developed by Altus, that may need to be
      modified to fulfill requirements for an FDA regulated product or other
      product.

ARTICLE 4. EXCHANGE OF TECHNICAL INFORMATION

Forthwith after the execution of this Agreement, both parties. shall disclose to
the other party Technical Information owned and possessed in the respective
field of which either party takes charge hereunder from time to time during the
life of this Agreement. All Technical Information that was exchanged between or
developed jointly by the parties [**********************************] shall be
deemed to be information exchanged between or developed jointly by the parties
pursuant to this Article 4. All intellectual property provisions in this
Agreement shall be effective as of the earliest date that the parties began
working together.

ARTICLE 5. SUPPLY OF MATERIALS

1.    ALTUS shall provide AMANO with forecasts setting out the amounts of
      Materials it expects it will require for each month during the [********]
      period from the time of preparation of the relevant forecast. The
      forecasts shall be updated [********]. ALTUS shall prepare a separate
      forecast for the [**********] required for any [*********************].
      Upon ALTUS's request, AMANO shall supply ALTUS with reasonable quantities
      of Materials manufactured by AMANO in accordance with Specifications,
      regardless of fully finished or not, be necessary for ALTUS's Development.

2.    If ALTUS places an order for Materials with AMANO for the purpose of
      ALTUS's Development pursuant to this Agreement that does not exceed the
      amount of Materials set forth in the most recent forecast for the relevant
      month, AMANO shall [**************************************; provided,
      however, if ALTUS places an order for Materials in excess of the volume
      specified in the applicable forecast, supply by AMANO of such excess
      Materials shall be subject to [***********************************] and
      to [************************************************]. Supply of Materials
      by AMANO hereunder may be conducted through AMANO's subsidiary, Amano
      Enzyme USA Co., Ltd. based in U. S. A.

3.    The parties hereto shall make a supply contract or contracts in accordance
      with the terms of this Agreement, on a bona fide basis, from case to case
      relating to the supply of Materials as provided hereinabove. The supply
      contract shall definitely provide terms

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       4
<PAGE>

      and conditions including but not limited to kind of Materials, quantities,
      Specifications, time of shipment, trade terms, price, payment and etc.

4.    AMANO shall not supply [**************] other than to ALTUS without prior
      written consent from ALTUS except as otherwise provided in Article 12.3,
      provided that nothing herein contains any restriction of supplying other
      party than ALTUS with any of Amano Enzymes or materials manufactured
      [***************************************] and/or other technologies of any
      third party.

5.    Being understood that evaluate, use or application of Materials and
      Specifications for medical products are decided by ALTUS at its sole
      discretion, AMANO shall incur no liability on Materials supplied
      hereunder, whatsoever for (a) all or any consequential or indirect losses
      or damages or loss of profit suffered or incurred by ALTUS or any third
      party howsoever caused; or (b) all or any actions, proceedings, demands or
      claims made against ALTUS or any third party by any person whatsoever,
      provided AMANO prepares the Materials in accordance with the
      Specifications and Good Manufacturing Practices. ALTUS shall indemnify and
      hold AMANO harmless from all cost, expense and liability arising out of or
      related to injury to persons or property resulting from ALTUS's use of
      Materials, provided AMANO prepares the Materials in accordance with the
      Specifications and Good Manufacturing Practices. ALTUS halt obtain and
      maintain, at its own expense, during the life of this Agreement and
      thereafter, sufficient insurance covering product liability, tort
      liability and other liability relating to Materials and Products written
      by an insurer satisfactory to AMANO and in which insurance AMANO shall be
      named as additional insured.

ARTICLE 6. JOINT DEVELOPMENT COMMITTEE

1.    ALTUS and AMANO shall, within [**********] after the execution of this
      Agreement, establish a Joint Development Committee ("JDC") to (a)
      elaborate and confirm the plan of Development contemplated herein; (b)
      give each other the progress condition of Development at the time of the
      meeting; (c) oversee the compliance of the facility with Good
      Manufacturing Practices and the transfer of the prototype process of
      manufacturing Materials from ALTUS to AMANO; (d) coordinate Development to
      the manufacturing process of Materials; and (e) to exercise decision
      making authority, and, further, shall make the plan and schedule of
      Development within [**********] after the first meeting of JDC.

2.    The JDC shall be comprised of [*****] ALTUS representatives and [*****]
      AMANO representatives, who will initially be the business and technical
      mangers. Each party may replace its JDC representative at any time, after
      discussion with the other party, with subsequent written notice to the
      other party.

3.    Decisions of the JDC shall be made by consensus approval. In the event the
      parties are unable to agree on any issue, the dispute will be referred to
      the President or a person designated by the President of each party, who
      shall promptly meet in person or by means of telephone or video conference
      and endeavor to resolve the dispute in a timely manner.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       5
<PAGE>

      In the event such individuals are unable to resolve the dispute, it shall
      be settled by [***************], or as otherwise agreed.

4.    On and after the execution of this Agreement, the JDC shall meet at least
      quarterly at regular intervals, or more often as agreed by the parties, in
      person at such locations as the parties agree, or by means of telephone or
      video conference. With the consent of the parties, other representatives
      of each party may attend JDC meetings as nonvoting observers.

5.    Each party shall each bear the expenses of their respective JDC members
      related to their participation on the JDC and attendance at JDC meetings.

ARTICLE 7. EXPENSES

1.    Each party hereto shall [*************************], including but not
      limited to, the [**************] in its laboratory
      [***********************] for Development from time to time, and such
      party [***********************************************].

2.    During ALTUS's stay in Japan for Development, ALTUS may,
      [***************], use all equipment in AMANO's laboratory, which are
      necessary for Development, and, during AMANO's stay in U.S.A. for
      Development, AMANO may, [****************], use all equipment in ALTUS's
      laboratory, which are necessary for Development.

3.    Each party hereto [**********************], including but not limited to,
      [********* *************] from U.S.A. to Japan and back,
      [**************************************************], which would be
      incurred on ALTUS or AMANO under this Agreement.

ARTICLE 8. PATENTS AND ETC.

1.    Subject to Article 8(4) below, Patents and/or other industrial property
      rights, inventions, discoveries, know-how and other technologies
      (collectively, "Intellectual Property Rights") solely developed, acquired
      or owned by either party during the life of this Agreement
      [*************************************************************
      *********************] Patents and/or other industrial property rights,
      inventions, discoveries, know-how and other technologies in any country
      without a prior written consent of such party.

2.    Each party [*****************************************] of Patents and/or
      other Intellectual Property Rights concerning all discoveries, inventions
      and/or other technologies acquired by such party in the course of or as
      the result of Development. The [***************] of such Intellectual
      Property Rights [******************] shall be ALTUS or AMANO and
      [*********************************************] for such Patents and/or
      other Industrial Property Rights [***************************].

3.    Each party [****************] for its own Intellectual Property Rights
      [***********************].

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       6
<PAGE>

4.    All Intellectual Property Rights which constitute Joint Technologies shall
      be the joint property of both parties. As to Joint Technologies resulted
      from Joint Development, Intellectual Property Rights for such Joint
      Technologies shall be applied and registered, in Japan and in any overseas
      countries, in both the names of ALTUS and AMANO as to the co-owners and
      the parties shall [************] in connection with such registrations;
      provided, however, that either party may refuse to apply for
      co-registration of Intellectual Property Right in case such party has, a
      sufficient reason not to apply or a thought to hold Joint Technologies as
      trade secrets; and that where one party refuses or fails to apply for
      co-registration of such Intellectual Property Rights within 90 days of a
      request for such co-registration by the other party without such a reason
      or a thought, then the other party shall be free at their own expense to
      file an application for registration of the Intellectual Property Rights
      as sole registrant and thereafter utilize such Intellectual Property
      Rights without any requirement to pay a royalty.

5.    Either party may not assign, transfer, sell or otherwise dispose of its
      Intellectual Property Rights and know-how acquired in Joint Development to
      any third party without a prior written consent of the other party. In
      case either party desires to dispose such technologies, the other party
      [***********************************************] as negotiated between
      the parties in good faith.

6.    Subject to the terms of this agreement, the parties [*****************]
      any Intellectual Property Rights they own in accordance with Articles 8(1)
      and (4) above, in any manner they deem fit, and
      [***********************************************], provided that, if
      either party desire to have a third party utilize any Joint Technologies,
      such either party shall obtain a prior written consent of the other party.

ARTICLE 9. PLAN, SCHEDULE AND REPORTS OF DEVELOPMENT

1.    Both the parties apply due diligence to Development in accordance with the
      plan and schedule of Development which should be prepared and amended from
      time to time during the life of this Agreement by mutual consultation.
      Provided, however, that; (a) in the event that Development of either party
      should be delayed by the force majeure or other reasonable causes to such
      party, the other party shall agree to the extension [*****************]
      in the plan and schedule of Development and continue Development during
      such extended period; (b) in case any alteration of a part of whole of the
      plan and schedule of Development is required by any reason, either of the
      parties having or knowing such reason shall notify the other party to that
      effect in advance.

2.    ALTUS and AMANO shall provide the other party with the written report on
      the results of Development [******************] reasonably requested by
      the other party.

ARTICLE 10. NDA APPLICATION

1.    ALTUS shall use best efforts to research, develop and conduct such
      research, development and preclinical and human clinical trials as
      necessary or desirable to obtain all regulatory approvals to manufacture
      and market, and to obtain necessary approval to

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       7
<PAGE>

      market, commence marketing and market Products in U. S. A. and any other
      countries in the world as ALTUS determines are commercially feasible.

2.    Within [**************] following the end of each [**********] period
      during the life of this Agreement, ALTUS shall prepare and deliver to
      AMANO a written report which shall describe, in reasonably sufficient
      detail, (a) the research performed to date employing Materials; (b) the
      progress of the development, and testing of Materials and Products in all
      studies including clinical trials; and (c) the status of obtaining the
      necessary approvals to market Products. In addition, ALTUS shall provide
      AMANO with a minimum of [**********] advance written notice of the
      contemplated filing of an NDA application, written notice of other
      significant regulatory filings and submissions in a timely fashion, and
      written notice of all approvals obtained after obtaining such approvals.

ARTICLE 11. COMMERCIALIZATION

1.    In case that Development of Materials and products contemplated hereunder
      has been completed and Products may be manufactured and sold on a
      commercial basis, [***************************] manufacture and sold
      Products by using all results from ALTUS's Development, AMANO's
      Development and Joint Development as well as Patents and Technical
      Information, and [**********************************************], and
      ALTUS shall [***************] to sell Products throughout the world.

2.    Notwithstanding the above, except as otherwise provided in this Agreement,
      [*********************************************] to manufacture and supply
      Materials [********] by using all results from ALTUS's Development,
      AMANO's Developments and Joint Development as well as Patents and
      Technical Information, and [************
      ***************************************] unless otherwise agreed in
      writing between the parties as to procurement of Materials from other
      manufacturing contractor or contractors than AMANO.

3.    Only ALTUS shall have a right to grant to the third party agreed upon by
      AMANO a license to manufacture Products by using all results from ALTUS's
      Development, Patents and Technical Information. Except as otherwise
      provided in this Agreement, in case ALTUS grants to the third party such a
      license, [*****************************
      *********************************************************************
      ******************************].

4.    In case ALTUS and/or its licensee procure Materials, which employ the
      results from AMANO's Development and Joint Development made hereunder,
      from other manufacturing contractor or contractors than AMANO, ALTUS, such
      licensee or such manufacturing contractor or contractors shall, unless
      otherwise provided herein, pay AMANO a royalty of [***************]
      manufactured and supplied by such manufacturing contractor or contractors
      pursuant to the rate and payment as agreed by AMANO in advance during
      commercialization.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       8
<PAGE>

5.    AMANO and ALTUS agree and acknowledge that it may be necessary during
      Phase III of the FDA clinical trial process to arrange for a separate
      manufacturer (the "Toll Manufacturer") that will be chosen jointly by
      AMANO and ALTUS to undertake certain manufacturing activities with respect
      to the [*********************************************************], and
      that for this purpose it will be necessary for AMANO and ALTUS to license
      to the Toll Manufacturer all of the necessary technology owned or licensed
      by AMANO and ALTUS. Accordingly, AMANO and ALTUS each agree to license
      such technology to such Toll Manufacturer on terms of confidentiality,
      Intellectual Property Right protection and other matters,
      [********************], reasonably satisfactory to AMANO and ALTUS.

6.    AMANO and ALTUS agree and acknowledge that in order to ensure future
      supply of Materials, it shall be necessary for ALTUS to engage a secondary
      supplier (the "Secondary Supplier"). AMANO and ALTUS therefore agree that,
      whilst it is intended that AMANO shall be the primary supplier of
      Materials, ALTUS may engage the Secondary Supplier which shall be entitled
      to use AMANO's Technologies on terms satisfactory to AMANO to produce
      quantities of Materials for use in clinical during the term of this
      Agreement.

7.    AMANO and ALTUS acknowledge that:

      (a)   ALTUS proposes to proceed with manufacture of the Products if FDA
            approval is obtained; and

      (b)   in order to pursue full-scale manufacture, the primary manufacturer
            of Materials will be required to have established a large facility
            suitable for commercial production of Materials in accordance with
            Good Manufacturing Practices; and

      (c)   the establishment of the production facility will necessarily
            involve considerable investment; and

      (d)   the party invested for such production facility including
            development works must recover such amount as invested from the
            business contemplated herein.

8.    ALTUS shall promptly deliver to AMANO all Phase II reports following
      completion of the Phase II clinical trial ("Phase H Completion") and
      statement showing definite estimation of quantities, prices of Materials
      and the Products to be manufactured and/or sold for [************] period
      commencing from the day entering Phase III. AMANO shall then advise ALTUS
      in writing within [***********] of its receipt of such Phase II reports
      whether AMANO intends to act as primary manufacturer of Materials,
      provided that the primary manufacture shall be deemed a manufacturing
      contractor who works for or on behalf of ALTUS to manufacture Materials.

9.    If AMANO decides to act as primary manufacturer of Materials following
      Phase II Completion, the parties shall proceed to negotiate in good faith
      a Manufacturing Agreement governing the manufacture and supply of
      Materials to be used by ALTUS in Phase III and/or the commercial
      manufacture and supply of Materials by AMANO. At

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       9
<PAGE>

      this stage, the parties tentatively expect the Manufacturing Agreement to
      include the following terms and conditions:

      (a)   AMANO shall supply at least [****] of the Materials used in the
            Products to ALTUS and a royalty shall be payable to AMANO in respect
            of any licensed AMANO's Technologies used in the manufacture of
            Materials manufactured by a Secondary Supplier, in an amount
            [***********************************];

      (b)   AMANO and ALTUS agree that they shall collaborate and share details
            of the process in order to drive down the costs of the Materials.
            Both AMANO and ALTUS shall share equal responsibility through a
            joint development team that will have the function of lowering costs
            of the Materials;

      (c)   AMANO and ALTUS shall negotiate and decide upon the target price of
            the Materials supplied by AMANO to have a target price equal to the
            greater of (i) [****] of the [***************] for the Product, or
            (ii) an amount that provides AMANO with a [****] margin.

10.   If AMANO decides not to act as primary manufacturer of Materials following
      Phase II Completion, ALTUS shall be forced to cease using AMANO as the
      primary manufacturer of Materials and engage an alternative primary
      manufacturer to carry out manufacture of Materials. In this case, AMANO
      agrees that the alternative primary manufacturer shall be entitled to use
      AMANO's Technologies and Joint Technologies for the purpose of manufacture
      of Materials, subject to the terms and conditions in Article 11.4.

11.   Where applicable, commercialization and transactions contemplated in this
      Article shall be executed under the separate agreements or contracts in
      writing to be duly signed by ALTUS and AMANO.

ARTICLE 12. RESTRICTION OF USE

1.    ALTUS and AMANO have provided the other party with some information on the
      subject herein contemplated under Secrecy Agreement dated [************]
      and shall further provide each other with some additional necessary
      information and materials, if available, so as to enable the other party
      to conduct Development.

2.    Neither ALTUS nor AMANO may use the information and materials supplied
      hereunder, which ALTUS and/or AMANO is obligated to keep confidential
      under Article 13 hereof for any purpose other than for fulfilling the
      purpose of this Agreement.

3.    AMANO agrees that it shall manufacture and supply
      [********************************************] to be used for the
      products exclusively to ALTUS during the term of this Agreement.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       10
<PAGE>

ARTICLE 13. CONFIDENTIALITY

1.    During the life of this Agreement and thereafter, unless otherwise agreed
      upon in writing between the parties hereto, ALTUS and AMANO shall hold in
      confidence any proprietary information provided by the other party and any
      study results, and not to disclose the same to any unauthorized third
      party by publication or otherwise without prior written consent by the
      other party, except for such information and results which:

      (a)   on the date of ALTUS's and AMANO's signing this Agreement is in the
            public domain;

      (b)   after the date of ALTUS's and AMANO's signing this Agreement becomes
            part of the public domain by publication or otherwise, except by
            breach of this Agreement by ALTUS and/or AMANO;

      (c)   ALTUS and/or AMANO can establish by competent proof that the
            information was in its possession on the date of its signing this
            Agreement and was not acquired directly or indirectly from the other
            party; and

      (d)   ALTUS and/or AMANO can establish by competent proof that the
            information was received from a third party after the date of its
            signing this Agreement; provided, however, that such information was
            not obtained by said third party directly or indirectly from the
            other party.

      (e)   is required to be disclosed by ALTUS to the FDA or other
            governmental authorities in order to obtain governmental approvals
            for the Products.

2.    It is mutually understood, however, that ALTUS or AMANO is allowed to
      disclose said information to a minimum number of investigators in their
      institutions to whom it is necessary for it to do so for the purpose of
      this Agreement on condition that such investigators shall be bound by the
      same obligation as provided in this Agreement.

3.    ALTUS and AMANO shall hold in confidence any and all negotiations with the
      other party including all past and future studies.

ARTICLE 14. PERIOD OF AGREEMENT

This Agreement shall become effective on the date first above written in this
Agreement and remain in force for a period of five (5) years thereafter, and
shall not be renewed thereafter unless agreed by both the parties hereto in
writing upon the extension of this Agreement at least six (6) months prior to
the date of expiration of this Agreement.

ARTICLE 15. TERMINATION

1.    If either party fails, refuses or neglects fully and faithfully to keep,
      observe or perform any covenant herein mentioned to be kept, observed or
      performed by either party, then, the other party may notify such party in
      writing of such default stating in such written notice the covenant or
      covenants of this Agreement which such party shall have failed,

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       11
<PAGE>

      refused or neglected to keep, observe or perform, and if such party, for a
      period of thirty (30) days after the service upon such party of such
      written notice, continues to fail, refuse or neglect to keep, observe or
      perform any such covenant or covenants, then the other party may cancel or
      terminate this Agreement by serving upon such party a written notice of
      such cancellation and termination hereof.

2.    ALTUS or AMANO may terminate this Agreement by giving the other party a
      written notice in the event of following:

      (a)   liquidation, dissolution, insolvency, bankruptcy or other events
            similar thereto of the other party, or

      (b)   incapability, incompetency or more than six (6) month absence of the
            other party.

3.    Either party hereto shall be entitled to cease any and all activity
      pursuant to this Agreement based on technical, scientific, medical,
      regulatory, economic or commercial factors upon one (1) year notice to the
      other party. In the event that such party gives the other party notice
      pursuant to this Article 15.3, this Agreement shall terminate after such
      one (1) year period has elapsed and such party shall not be required to
      pay any penalty, indemnity, damages or other amount to the other party
      based on the cessation of activity pursuant to this Article 15.3.

ARTICLE 16. EFFECT OF TERMINATION

1.    In case of termination of this Agreement: (i) by AMANO for ALTUS's
      material breach; or (ii) by ALTUS for reasons other than AMANO's material
      breach, ALTUS shall retain a royalty bearing license, for so long as the
      Products are sold, with right to sublicense, to AMANO's Technologies and
      Joint Technologies, to make, have made, use, sell, offer to sell and
      import Materials employing such AMANO's Technologies and Joint
      Technologies, the royalty shall be [****************] of net sales of the
      Products.

2.    In case of termination of this Agreement: (i) by ALTUS for
      [********************]; or (ii) by AMANO as a result of
      [*********************************************************], ALTUS shall
      retain a [***************] license, for so long as the Products are sold,
      with right to sublicense, to AMANO's Technologies and Joint Technologies,
      to make, have made, use, sell, offer to sell and import Materials and
      Products employing such AMANO's Technologies and Joint Technologies as
      developed during the effective period of this Agreement; [******].

3.    Upon the termination as set forth in Article 16.1 or Article 16.2, both
      the parties shall enter into a license agreement where AMANO grants ALTUS
      a license to [***********************************************] Materials
      and Products employing such AMANO's Technologies and Joint Technologies as
      developed during the effective period of this Agreement.

4.    Expiration or termination of this Agreement shall not relieve the parties
      of any obligation accruing prior to such expiration or termination

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       12
<PAGE>

5.    The following provisions shall survive termination: Articles 8, 11, 12,
      14, l6 and 17.

ARTICLE 17. ARBITRATION

All disputes, controversies or differences which may arise between the parties
hereto, out of or in relation to or in connection with this Agreement, or the
breach thereof, shall be finally settled by arbitration in:

      (a)   where the relevant claim is brought by ALTUS - Tokyo, Japan in
            accordance with the Commercial Arbitration Rules of The Japan
            Commercial Arbitration Association; or

      (b)   where the relevant claim is brought by AMANO - Massachusetts, United
            States of America, in accordance with the rules and procedures of
            the American Arbitration Association.

In either case, the award rendered by arbitrator(s) shall be final and binding
upon both parties.

ARTICLE 18. NOTICE

Any notice required of permitted to be given under this Agreement by either of
the parties hereto shall be deemed to have been sufficiently given for all the
purposes hereof if mailed by registered mail, postage prepaid, addressed to the
party to be notified at its address shown at the beginning of this Agreement, or
at such other address as may be furnished to the notifying party in writing.

ARTICLE 19. WAIVER

No omission or delay on the part of any party hereto in requiring a due and
punctual fulfillment by any other party hereto of the obligations of such other
parry shall be deemed to constitute a waiver by the omitting or delaying party
of any of its rights to require such due and punctual fulfillment of any other
obligations hereunder whether similar or otherwise or a waiver of any remedy it
might have hereunder.

ARTICLE 20. FORCE MAJEURE

Neither party to this Agreement shall be held responsible for the damages caused
by any delay or failure to perform under this Agreement, which is the result of
any happenings or events which could not have been reasonably avoided. Such
happenings or events shall include but shall not be limited to fire, flood,
explosion, action of the elements, acts of God, accidents, epidemics, inability
to obtain or shortage of material or equipment, riots, or other civil commotion,
war enemy action, or acts, demands or requirements of the Governments of U.S.A.
or Japan.

ARTICLE 21. ASSIGNMENT

Neither this Agreement nor any right or obligation hereunder shall be assignable
in whole or in part, whether by operation of laws, or otherwise by either party
without a prior written consent of the other party. In case of any amalgamation,
merger, consolidation or sale of all or substantially

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       13
<PAGE>

all the assets of ALTUS or AMANO without a prior written consent of the other
party, this Agreement and any right hereunder may
[********************************] except where
[*****************************************************************************
***************************], in such case such assignment shall require consent
from the other party, and such consent shall not be unreasonably withheld.

ARTICLE 22. GOVERNING LAW

1.    Irrespective of the place of execution or performance, this Agreement as
      to all matters except with one provided in Article 22 (2) below shall be
      considered as having been entered into in Japan and shall be construed and
      interpreted in accordance with the laws of Japan, excluding its Law
      Regarding Conflict of Laws (horei).

2.    Irrespective of Article 22(I) above, the laws of the United States of
      America (excluding its choice of law rules) shall apply to the extent that
      the provisions contained in this Agreement concern or deal with
      Intellectual Property Rights.

ARTICLE 23. AMENDMENT

This Agreement sets forth the only agreement and understanding of the parties on
the subject of cooperative development and supersedes any prior negotiations,
memorandum or agreement, whether oral or written, and neither of the parties
shall be bound by any conditions, definitions, warranties, or representations
other than as expressly provided in this Agreement, or as duly set forth on or
subsequent to the date hereof in writing and signed by a proper and duly
authorized officer of the party to be bound thereby.

ARTICLE 24. SEPARABILITY

The validity, legality and enforceability of any provision hereof shall not be
affected or impaired in any way by any holding that any other provision or
provisions contained herein are invalid, illegal or unenforceable in any
respect.

ARTICLE 25. LANGUAGE

This Agreement is in the English language only, which language shall control and
any version in any other language shall be for accommodation only and not bind
the parties hereto.

ARTICLE 26. HEADINGS

The heading of articles and paragraphs used in this Agreement are inserted for
convenience of reference only and shall not affect the interpretation of the
respective articles and paragraphs of this Agreement.

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       14
<PAGE>

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed on the
day and year first above written. This Agreement is made in English, two copies
and both parties duly signed and retain each other.

ALTUS: ALTUS BIOLOGICS INC

    /s/ Peter Lanciano
-----------------------------------
By Peter Lanciano, President

AMANO: AMANO ENZYME CO., LTD.

    /s/ Motoyuki Amano
-----------------------------------
By Motoyuki Amano; President

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       15
<PAGE>

                 Amendment to Cooperative Development Agreement

THIS AMENDMENT, entered into as of the 11th day of October, 2005 (this
"Amendment"), by and between Altus Pharmaceuticals Inc. (formerly known as Altus
Biologics Inc.), a corporation organized and existing under the laws of the
State of Delaware and having its principal place of business at 125 Sidney
Street, Cambridge, Massachusetts 02139, USA ("Altus"), and Amano Enzyme Inc., a
corporation organized and existing under the laws of Japan and having its
principal place of business at 1-2-7, Nishiki, Naka-ku, Nagoya, Japan ("Amano"),
amends the Cooperative Development Agreement dated as of November 8, 2002, by
and between Altus and Amano (the "Agreement"). Capitalized terms used in this
Amendment and not defined in this Amendment shall have the meanings ascribed to
them in the Agreement.

                                   Background

WHEREAS, Altus and Amano desire to amend the Agreement to set forth certain
mutual understandings reached by the parties with respect to the manufacture and
supply of Materials by Amano for use by Altus in certain non-clinical studies
and the phase III clinical trial of the Product (collectively, the "Phase III
Materials") and the engagement of third party contract manufacturers ("CMOs") to
provide manufacturing services in connection with commercial manufacture and
supply; and

WHEREAS, Altus and Amano desire to amend the Agreement to set forth certain
additional understandings in anticipation of (a) the parties entering into a
Manufacturing Agreement for the commercial manufacture and supply of Materials
by Amano (if Amano elects to act as the primary manufacturer of some of the
Materials for commercial supply, it being understood by the parties that Amano
does not currently anticipate that it will elect to act as the initial primary
manufacturer of all of the Materials for commercial supply) and (b) the
engagement of CMOs for the commercial manufacture and supply of Materials for
which Amano does not elect to act as the primary manufacturer for commercial
supply.

NOW, THEREFORE, Altus and Amano agree to amend the Agreement as follows:

1. The parties acknowledge that certain provisions of the Agreement anticipate
that, if Amano elects to act as the primary manufacturer of Materials following
phase II Completion, the parties will negotiate a Manufacturing Agreement to
govern the manufacture and supply of Materials for both the Phase III clinical
study and the commercial supply of Products. Notwithstanding such provisions,
the parties have agreed to proceed with the manufacture and supply of Phase III
Materials as set forth below in this Amendment and to defer negotiation of a
Manufacturing Agreement until promptly after Amano makes its election pursuant
to paragraph 2 below.

2. The parties expect to reach agreement regarding Altus' anticipated needs for
commercial supply and Amano's manufacturing capacity and capabilities prior to
[***************]. With respect to Materials for which Amano has
[*************************], Amano shall make its election as to whether it will
act as the initial primary manufacturer for commercial supply on or about
[***************]. The timing of such election is critical to (a) enabling the
parties to negotiate a Manufacturing Agreement, if Amano elects to act as the
primary manufacturer for

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       16
<PAGE>

some of the Materials, and (b) enabling Altus to engage CMOs to assist in the
manufacture of Materials necessary for commercialization, all in a timeframe
that is consistent with Altus' commercial launch goals for the Product. Amano's
right to elect to act as the initial primary manufacturer of any or all of the
Materials for commercial supply shall be subject to Altus' right under the
Agreement to engage a Secondary Supplier for up to [*****] of any such Material.
Amano and Altus expect that the Manufacturing Agreement will provide that if
Amano [****** ***********] the initial primary manufacturer of any or all of the
Materials for commercial supply, but at a later date notifies Altus that it
wishes to become the primary manufacturer of any such Materials, the parties
shall [*********************************************************************] on
mutually agreeable terms; provided that any such transition shall be
accomplished in a manner that does not [**************************************
***].

3. The parties are currently in the process of engaging a CMO selected by the
parties to perform [***********************] in connection with Amano's
manufacture and supply of Phase III Materials. The costs of such CMO's services
shall be borne by [*****].

4. Amano shall supply GMP-compliant Phase III Materials and non-GMP compliant
non-clinical material at the following prices (excluding shipping charges):

         [*******]:    [*********] per kilogram

         [******]:     [********] per kilogram

         [******]:     [********] per kilogram

The currently anticipated requirements and delivery schedule for such Phase III
Materials to be supplied by Amano is set forth in Exhibit A to this Amendment.
Altus shall provide Amano, with updates to the requirements and delivery
schedule set forth in Exhibit A on a [******] basis until such time as Altus
provides Amano with firm purchase order(s) for such Phase III Materials, each of
which shall be provided at least [*****] prior to the final delivery date for
the Phase III Materials covered by such purchase order. Amano shall accept such
purchase order(s) and shall deliver such Phase III Materials in accordance with
such purchase order(s) to Altus' designated location(s); provided that Amano
shall not be required to provide more than [***] of the quantities set forth in
Exhibit A and Amano shall not be required to deliver Phase III Materials other
than [***************************************] set forth in Exhibit A.

5. Promptly after the date of this Amendment, the parties shall enter into a
quality agreement relating to Amano's supply of Phase III Materials, which
agreement shall address operational issues relating to manufacturing quality
typically addressed in pharmaceutical manufacturing quality agreements. The
Phase III Materials that Amano supplies shall conform to the requirements
therefor specified in Exhibit A and in the quality agreement described in this
paragraph 5; provided that the parties acknowledge that, as of the date of this
Amendment, certain aspects of [************************************************
************************************************] and the parties agree to
reasonably cooperate with one another to amend Exhibit A and the quality
agreement as needed to reflect [**************************].

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       17
<PAGE>

6. The parties agree that CMOs required to provide manufacturing services in
connection with the commercial manufacture and supply of Materials shall be
selected in accordance with the criteria set forth in Exhibit B and that Amano
and Altus shall work collaboratively through the JDC to select such CMOs and
decide upon the desired logistics with respect to interactions of such CMOs,
Amano and Altus in a timely manner so that Materials can be delivered on or
before Altus' required delivery dates. Because the selection of satisfactory
CMOs in a timely manner is of critical importance to Altus' regulatory and
product development responsibilities, [****************************************]
regarding the selection of any CMO [*******************************************
**************]. Unless otherwise agreed by the parties on a case-by-case basis,
Altus will contract with and supervise any requited CMOs. It is anticipated that
Altus will be responsible for [******************] costs to the extent
[*********************].

7. Amano and Altus shall cooperate with each other to promptly transfer any
necessary manufacturing technology to any CMO selected in accordance with this
Amendment. The manufacturing technology that Amano and Altus would transfer
would include, without limitation, any Technical Information, copies of
documentation possessed by Amano or Altus, and [**********************]
reasonably required to produce the Materials, in each case organized and
delivered in a manner reasonably designed to enable the transferee to make
efficient use of such technology. [*********************************************
********************************************************************************
**************].

8. Amano shall grant licenses to use AMANO's Technologies and Joint Technologies
to Altus with a right to grant sublicenses thereof to any CMOs described in
paragraph 7 of this Amendment reasonably required to enable CMOs to manufacture
Materials for commercial supply to Altus. For the purposes of clarifying Section
4 of Article 11 of the Agreement, Altus shall be responsible for making royalty
payments to Amano under that section and the royalty to be paid by Altus to
Amano with respect to Materials manufactured and supplied by a CMO using AMANO's
Technologies and/or Joint Technologies shall be [***] of [********************
******************************************].

9. If Amano elects to act as the initial primary manufacturer of some of the
Materials for commercial supply, the parties shall negotiate pricing for such
supply in connection with their negotiation of the Manufacturing Agreement
[******************************************************************************
*********************************].

10. The parties acknowledge that substantial communication and cooperation will
be needed in order to facilitate the timely manufacture and supply of Materials
for the Phase III clinical trial of the Product and for commercial supply. The
parties agree to coordinate their activities with respect to such manufacture
and supply matters through the JDC and to use reasonable efforts to undertake
such activities in a manner consistent with the best commercial interests of the
Product.

11. Without limiting Amano's exclusivity obligations set forth in Articles 5.4
and 12.3 of the Agreement, Amano shall not [************************************
********************************************************************************

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       18
<PAGE>

********************************************************************************
********************************************************************************
*******************************************************]; provided, however, for
the avoidance of doubt, the parties agree that Amano shall be permitted to
market, sell and supply [*******************************************] provided
in each case such enzymes are [*************************************************
**********************]; and provided further, however, Amano shall be permitted
to continue supplying the enzymes that it currently supplies to customers (other
than Altus) if, [**************************************************************
*******************************************************************************
***********************************************************************].

12. As amended by this Amendment, the Agreement remains in full force and
effect.

EXECUTED by the parties as of the date first written above.

ALTUS PHARMACEUTICALS INC.

By: /s/ Sheldon Berkle
    -------------------------------
Name: Sheldon Berkle
Title: President & CEO

AMANO ENZYME INC.

By: /s/ M. Amano
    -------------------------------
Name:  Motoyuki Amano
Title:  President

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       19
<PAGE>

                                    Exhibit A

Currently Anticipated Requirements and Delivery Schedule for Phase III Materials
                            to be Supplied by Amano

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       20
<PAGE>

                                    Exhibit B

                                  CMO Criteria

1.    Capacity/Capability

      1.2   [***]

2.    Timing - CRITICAL

      2.2   Ability to meet launch timeline

      2.3   Complete timeline through [***]

3.    Quality

      3.2   [***]

      3.3   Inspection Status and Experience

4.    Cost

      4.2   Capital costs - [***].

      4.3   Product cost (COGs)

      4.4   Start-up cost - For each [***].

PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE
SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT.

                                       21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}]]